TELO logo

TELOMIR PHARMACEUTICALS INC

TELONASDAQ
🏆 #4110 by market capEarnings Nov 9US Equity
$1.07▲ $0.05 (+4.90%)
Latest quote
🔔
Track TELO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.9%
7d▲ 8.6%
14d▲ 1.9%
30d▼ 9.3%
ytd▼ 19.5%
1y▼ 29.1%
🏦Market Cap
$79M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.07 – $1.07
52-Week Range
$0.89 – $1.58
Volume (shares)
284
Avg Volume (shares)
—
Shares Outstanding
73.6M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.15
Dividend Yield
—
Dilution (1yr)
+16.4%
TELO logo

TELOMIR PHARMACEUTICALS INC

TELO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −13.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −27.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
34.4M▲ +16.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$6M YoY
StockOtter · stockotter.space

About TELOMIR PHARMACEUTICALS INC

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.